Both Compound I and Compound II have redox potentials of approximately +1 V (Veitch 2004).
Both compound 2 and compound 3 show a strong Ag Ag interaction.
Furthermore, both compound 4a and 7b, as well as compound 6a, completely diminished egg deposition.
In both Compound and Substance, the ten top-ranked atom environments consist of carbon, nitrogen and oxygen only.
Finally, the current case study illustrates a need for careful consideration of both compound dose and systemic solubility prior to utilizing nanosuspension as a mode of intravenous delivery.
Echocardiographic and histological analysis revealed that both Compound A and NBD inhibit cardiac NF-κB activity and prevent the development of tumor-induced systolic dysfunction and atrophy.
Our results reveal a potent inhibition of both compound 1 (IC50 9.01±0.01 µM) and 2 (IC50 11.65±6.20 µM) (Mean±S.E.M). on COX-2-dependent PGE2 production.
Both compound 5 and 6, showed significant activity against colon cancer (COLO-205) and cervical cancer (HeLa) and moderate with others.
Both compound series have been tested on the Adenosine A2A receptor but in the former case it was obtained from bovine striatal membrane and the latter explicitly mentions human Adenosine A2A receptors.
The relative position of GRAS and Carcinogenic sets in the CDPs (quadrant in blue) indicates that both compound collections have relative low MACCs keys/Tanimoto similarity but low chemotype diversity (e.g., high AUC or low F50 values).
In the above example, when there are both compound registry and complex registry available, then Compound identifiers and Complex identifiers need to be prefixed with "compounds/" and "complexes/", respectively.
